Kryger Capital’s Cidara Therapeutics CDTX Stock Holding History

Kryger Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-185,313	Closed	-$40.9M	–	78
2025 Q4	$40.9M	Buy	+185,313	New	+$30M	3.16%	15

Kryger Capital's CDTX Position: Q1 2026 in Review

Kryger Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 185,313 shares — an estimated $40.9M sold.

Kryger Capital first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $40.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Kryger Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Kryger Capital sold 185,313 Cidara Therapeutics shares in Q1 2026, an estimated $40.9M.
Kryger Capital first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Kryger Capital's Cidara Therapeutics position peaked at $40.9M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Kryger Capital's 13F filing for Q1 2026, filed 14 May 2026.